Moving From Talking To Action
The OpenTox Hackathon Case Studies will provide datasets, background knowledge and a set of scientific challenge questions to participants to develop answers to. Participants will work in groups to engage in scientific discussion, to apply analysis methods to the data, and to develop new strategies to apply to solve the problems. Technical participants in the event may write code, hack combinations and create mashups in support of the analysis. Virtual participation will be possible through the event with task assignment from Baltimore to the virtual participants and status and results return possible from them, as shown to all on a running tasks board running across all cases.
The proceedings of the Hackathon event will be processed for dissemination purposes, providing credit to all participants, and additionally serving as one valuable input into the OpenTox Euro 2016 and OpenTox Asia 2016 events taking place in Autumn 2016, where further ongoing progress will be attempted at their hackathon events, thus providing a global community involvement and dissemination for the ongoing practice, methods and tools development. Individual case studies will also be progressed in a variety of ways e.g., as contributions to practice or guidance documents and papers related to specific cases and to propose the generation of next experiments, data and models.
1. Case study 1: Ab initio based Risk Assessment of a Cosmetics Ingredient
2. Case study 2: Meta Analysis of Evidence on ToxBank Gold Compounds supporting AOP development and Risk Assessment
3. Case study 3: Read Across supporting the Reduction of Animal Testing within a Regulatory Context
4. Case study 4: Predicting the Adverse Outcomes of Drugs using Alternative Evidence and its Pragmatic Validation
5. Case study 5: Air quality and acute mortality
6. Case study 6: Analyzing local validity for read-across prediction of systemic toxicity using chemical and biological information
7. Case study 7: Hindered Phenol Case Study - Health Canada and US EPA
8. Case study 8: Variability and Uncertainty in In Vivo Data